The Trump administration has moved to reclassify cannabis under federal law, shifting it from a Schedule I to a Schedule III substance, according to a statement from the U.S. Department of Justice. The report said the change could expand scientific research while maintaining federal controls.
Under the new framework, FDA-approved cannabis-based products and state-regulated medical marijuana items will be treated as Schedule III drugs. According to the report, this classification recognises medical use and reduces regulatory barriers that have limited clinical research.
Trump administration reclassifies cannabis in major shift that could expand scientific research https://t.co/VblnOMAfaY
— CNBC (@CNBC) April 23, 2026
The Justice Department said the move will also provide clarity for patients, researchers and providers. Financially, the shift could allow cannabis businesses to access tax deductions and banking services previously restricted under federal law.
The report noted that a formal review process is still underway, with hearings expected. The policy marks a significant shift in federal drug regulation, signalling a more pragmatic approach to cannabis research and oversight.
Also Read:
TIPP Staff
